Free Trial

Boston Scientific (BSX) Stock Price, News & Analysis

Boston Scientific logo
$100.29 -0.62 (-0.62%)
As of 01/22/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Boston Scientific Stock (NYSE:BSX)

Key Stats

Today's Range
$100.14
$101.65
50-Day Range
$86.98
$100.90
52-Week Range
$59.85
$101.65
Volume
8.17 million shs
Average Volume
5.73 million shs
Market Capitalization
$147.81 billion
P/E Ratio
82.88
Dividend Yield
N/A
Price Target
$97.26
Consensus Rating
Moderate Buy

Company Overview

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
93rd Percentile Overall Score

BSX MarketRank™: 

Boston Scientific scored higher than 93% of companies evaluated by MarketBeat, and ranked 109th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Boston Scientific has received a consensus rating of Moderate Buy. The company's average rating score is 2.96, and is based on 20 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Boston Scientific has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Boston Scientific's stock forecast and price target.
  • Earnings Growth

    Earnings for Boston Scientific are expected to grow by 12.60% in the coming year, from $2.46 to $2.77 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Boston Scientific is 82.88, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.59.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Boston Scientific is 82.88, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.11.

  • Price to Earnings Growth Ratio

    Boston Scientific has a PEG Ratio of 2.59. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Boston Scientific has a P/B Ratio of 7.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Boston Scientific's valuation and earnings.
  • Percentage of Shares Shorted

    0.99% of the outstanding shares of Boston Scientific have been sold short.
  • Short Interest Ratio / Days to Cover

    Boston Scientific has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Boston Scientific has recently increased by 17.76%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Boston Scientific does not currently pay a dividend.

  • Dividend Growth

    Boston Scientific does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.99% of the outstanding shares of Boston Scientific have been sold short.
  • Short Interest Ratio / Days to Cover

    Boston Scientific has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Boston Scientific has recently increased by 17.76%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Boston Scientific has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 27 news articles for Boston Scientific this week, compared to 19 articles on an average week.
  • Search Interest

    50 people have searched for BSX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • MarketBeat Follows

    17 people have added Boston Scientific to their MarketBeat watchlist in the last 30 days. This is an increase of 70% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Boston Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,702,261.00 in company stock.

  • Percentage Held by Insiders

    Only 0.50% of the stock of Boston Scientific is held by insiders.

  • Percentage Held by Institutions

    89.07% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Boston Scientific's insider trading history.
Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

BSX Stock News Headlines

Do this Before Elon’s Reveal on January 29th
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Boston Scientific price target raised to $111 from $86 at Barclays
RBC Capital Reaffirms Their Buy Rating on Boston Scientific (BSX)
Truist Financial Gives a Buy Rating to Boston Scientific (BSX)
See More Headlines

BSX Stock Analysis - Frequently Asked Questions

Boston Scientific's stock was trading at $89.32 at the start of the year. Since then, BSX shares have increased by 12.3% and is now trading at $100.2890.
View the best growth stocks for 2025 here
.

Boston Scientific Co. (NYSE:BSX) announced its quarterly earnings results on Wednesday, October, 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. The company's quarterly revenue was up 19.3% on a year-over-year basis.
Read the conference call transcript
.

Boston Scientific subsidiaries include VertiFlex, BTG, Augmenix, Veniti, Claret Medical, Cryterion Medical, nVision Medical, and more.

Boston Scientific's top institutional investors include KBC Group NV (0.16%), Assenagon Asset Management S.A. (0.06%), ZWJ Investment Counsel Inc. (0.04%) and Gateway Investment Advisers LLC (0.04%). Insiders that own company stock include Michael F Mahoney, Daniel J Brennan, Joseph Michael Fitzgerald, Jeffrey B Mirviss, Edward J Ludwig, Edward J Ludwig, John Bradley Sorenson, Jonathan Monson, Eric Francis Yves Thepaut, Wendy Carruthers, Vance R Brown, Nelda J Connors, Arthur C Butcher, Charles J Dockendorff, Ian T Meredith, David A Pierce and Scott Olson.
View institutional ownership trends
.

Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Boston Scientific investors own include BlackRock (BLK), Broadcom (AVGO), ServiceNow (NOW), UnitedHealth Group (UNH), The Goldman Sachs Group (GS), NVIDIA (NVDA) and Illinois Tool Works (ITW).

Company Calendar

Last Earnings
10/23/2024
Today
1/22/2025
Next Earnings (Estimated)
1/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
10113710
Employees
48,000
Year Founded
1979

Price Target and Rating

Average Stock Price Target
$97.26
High Stock Price Target
$110.00
Low Stock Price Target
$68.00
Potential Upside/Downside
-3.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.96
Research Coverage
23 Analysts

Profitability

Net Income
$1.59 billion
Pretax Margin
13.84%

Debt

Sales & Book Value

Annual Sales
$14.24 billion
Cash Flow
$2.95 per share
Book Value
$13.33 per share

Miscellaneous

Outstanding Shares
1,473,830,000
Free Float
1,466,458,000
Market Cap
$147.81 billion
Optionable
Optionable
Beta
0.80

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NYSE:BSX) was last updated on 1/23/2025 by MarketBeat.com Staff
From Our Partners